You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Ocugen计划今年在美出售1亿剂新冠疫苗 下月申请紧急使用授权
阿思达克 03-16 09:45
美国生物制药公司Ocugen(OCGN.US)行政总裁Shankar Musunuri对《路透社》表示,目标第二季在美国出售印度合作伙伴Bharat Biotech的新冠疫苗Covaxin,预计全年销量为1亿剂。

Musunuri称,疫苗最初会从国外进口,之後会开始在美国生产,目前已经与美国食品与药物管理局(FDA)展开初步会谈,计划在4月寻求紧急使用授权。

美国现时授权辉瑞疫苗用於16岁及上人士,Musunuri表示,两剂COVAXIN的有效率为81%,兼且对所有儿童、高危人士及孕妇等都是安全的。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account